AbbVie (NYSE:ABBV) Updates FY 2025 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 10.380-10.580 for the period, compared to the consensus estimate of 11.990. The company issued revenue guidance of -. AbbVie also updated its Q3 2025 guidance to 1.740-1.780 EPS.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ABBV. Cantor Fitzgerald lifted their price target on shares of AbbVie from $215.00 to $245.00 and gave the company an “overweight” rating in a research report on Monday, September 15th. Citigroup lifted their price objective on shares of AbbVie to $205.00 and gave the company a “hold” rating in a report on Wednesday, June 11th. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Bank of America raised their price target on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday. Finally, Guggenheim boosted their price objective on AbbVie from $216.00 to $227.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $228.22.

AbbVie Stock Down 1.1%

AbbVie stock opened at $234.07 on Friday. AbbVie has a fifty-two week low of $163.81 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The firm’s 50-day simple moving average is $210.77 and its 200 day simple moving average is $195.90. The stock has a market cap of $413.49 billion, a PE ratio of 111.46, a price-to-earnings-growth ratio of 1.37 and a beta of 0.51.

AbbVie (NYSE:ABBV) last posted its earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing the consensus estimate of $3.24 by ($0.27). AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. During the same period in the prior year, the business earned $2.65 EPS. AbbVie’s quarterly revenue was up 6.6% compared to the same quarter last year. Research analysts predict that AbbVie will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 14th. Shareholders of record on Wednesday, October 15th will be given a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 annualized dividend and a yield of 2.8%. AbbVie’s payout ratio is currently 312.38%.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 13,295 shares of the firm’s stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the sale, the executive vice president directly owned 58,247 shares of the company’s stock, valued at $11,562,611.97. This trade represents a 18.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Rakuten Securities Inc. increased its stake in shares of AbbVie by 26.5% during the 2nd quarter. Rakuten Securities Inc. now owns 368 shares of the company’s stock worth $68,000 after purchasing an additional 77 shares during the last quarter. Binnacle Investments Inc grew its holdings in AbbVie by 33.2% during the second quarter. Binnacle Investments Inc now owns 493 shares of the company’s stock valued at $92,000 after purchasing an additional 123 shares during the period. Darwin Wealth Management LLC purchased a new stake in AbbVie in the second quarter worth $277,000. Redwood Financial Network Corp raised its stake in shares of AbbVie by 10.8% in the second quarter. Redwood Financial Network Corp now owns 1,649 shares of the company’s stock valued at $306,000 after buying an additional 161 shares during the period. Finally, WFA of San Diego LLC purchased a new position in shares of AbbVie during the 2nd quarter valued at $333,000. 70.23% of the stock is owned by institutional investors.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.